AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)’. The study aims to evaluate the effectiveness of a triple therapy inhaler on cardiopulmonary outcomes in COPD patients at high risk, highlighting its potential significance in improving treatment protocols.
Intervention/Treatment: The study tests two inhalation treatments: BGF MDI, a combination of Budesonide, Glycopyrronium, and Formoterol Fumarate, and GFF MDI, comprising Glycopyrronium and Formoterol Fumarate. These treatments aim to improve cardiopulmonary outcomes in COPD patients.
Study Design: This is an interventional, randomized, double-blind study with a parallel group model. It involves quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations, focusing on treatment as the primary purpose.
Study Timeline: The study began on February 21, 2024, with recruitment currently ongoing. The last update was submitted on July 18, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results that could influence treatment approaches.
Market Implications: This study could significantly impact AstraZeneca’s stock performance by potentially enhancing its COPD treatment portfolio. Positive outcomes may boost investor confidence and position AstraZeneca favorably against competitors in the respiratory treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.